Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
19 evidence topics · 24 sources
Summary
- Guideline positioning of targeted biologics: Guidance states that clinicians should seek to initiate available targeted therapies in patients with gMG who have active symptoms and for whom conventional therapy does not achieve symptom control within 6 to 12 months or results in excessive treatment-related burden, with use as initial treatment driven by clinician judgment. Complement and FcRn inhibitors are recommended as second- or third-line treatment in severe MG exacerbations and crisis, and their roles are being established especially in patients unresponsive to conventional therapy. Expert recommendations state that an interclass switch should be considered for inefficacy, intolerable side effects, or patient preferences regarding type and frequency of administration, and that a switch to IVIg interval therapy should be considered when targeted immunotherapies fail.
- Intended population and setting for Descartes-08: The phase 3 AURORA trial enrolls adults with acetylcholine receptor autoantibody-positive generalized MG and administers six once-weekly outpatient infusions without preconditioning chemotherapy. The company states that the current standard of care consists of chronic steroids and other immunosuppressants and that complement and FcRn inhibitors are typically administered continually, estimates that MG affects over 106,000 patients in the U.S., and describes Descartes-08 as the only CAR-T in autoimmune disease it is aware of that is designed for outpatient administration without preconditioning chemotherapy. The company states that conventional DNA cell therapies are administered under close monitoring in an inpatient setting. Investigators of an earlier Descartes-08 study reported the feasibility of preparing the cells for patients on immunosuppressive therapy, using them without lymphodepletion chemotherapy, and administering them in the outpatient setting with minimal post-infusion monitoring, and a later publication describes a “biologic-like approach that involves an initial leukapheresis”. An investigator quoted by the company described outpatient retreatment without lymphodepleting chemotherapy as a potential option for patients who have cycled through multiple therapies.
- Recommendations on cellular therapy: EBMT recommendations state that cellular therapy in autoimmune diseases should be performed within a clinical trial whenever possible, at expert centres with JACIE accreditation for immune effector cell administration, that the need for and dose of lymphodepletion are not established, and that repeated dosing of BCMA CAR-T has been efficacious in MG without lymphodepletion. A 2026 article on CAR-T therapy in autoimmune disease states that current neurological evidence is limited to small early-phase studies and case reports, with one placebo-controlled trial (generalised MG), and that CAR-T therapy should be considered experimental and delivered in specialised centres.
- Other CAR-T approaches in MG: In a study of anti-BCMA/CD19 bispecific CAR-T cells given as a single infusion after fludarabine and cyclophosphamide lymphodepletion, 18 participants were enrolled; grade 1 cytokine release syndrome occurred in 39%, and among 17 who completed follow-up, MG-ADL improved by −8.6 (95% CI −10.2 to −7.0) and QMG by −15.4 (−17.6 to −13.2) by day 180, and 14 (82%) achieved minimal manifestations. Three patients with treatment-resistant MG treated with anti-CD19 CAR-T cells (KYV-101) after cyclophosphamide and fludarabine lymphodepletion achieved sustained remission for at least 19 months, and BCMA-directed CAR-T cells in two patients (one AChR-IgG, one MuSK-IgG) produced clinical improvement over 18 months. KYV-101 is being compared with standard-of-care immunosuppressive therapy in the phase 2/3 KYSA-6 study, and CABA-201 is being evaluated with cyclophosphamide and fludarabine and, at escalating doses, without that preconditioning.
- REMS change for approved CAR-T therapies: The FDA eliminated the REMS for currently approved BCMA- and CD19-directed autologous CAR T cell immunotherapies, removing the requirements for specially certified dispensing sites with on-site, immediate access to tocilizumab. Labeling now calls for monitoring for at least two weeks, including daily monitoring for at least one week, remaining near a healthcare facility for at least two weeks, and avoiding driving for two weeks. In 58 patients with myeloma, lymphoma, or acute lymphoblastic leukemia who received CAR T-cell infusion as outpatients and were seen daily for the first 7 to 10 days, 17 (41%), 16 (38%), and 9 (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30.
Company statement of unmet need with chronic immunosuppression and continually administered biologics
Company estimate of the U.S. myasthenia gravis population and market opportunity
Positioning as an outpatient CAR-T without preconditioning chemotherapy
Care setting compared with conventional DNA-based CAR-T cell therapy
“This study demonstrated the feasibility of preparing autologous RNA CAR T-cells (rCAR-T) for patients on immunosuppressive therapy, of using the cells without lymphodepletion chemotherapy, and of administering rCAR-T in the outpatient setting with minimal post-infusion monitoring due to the notable safety profile of the product.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While DNA-based CAR T-cell therapies are also moving to the outpatient setting, they still require close post-infusion monitoring with daily clinic visits as well as reservation of hospital beds in case severe toxicities develop.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Investigator statement on use after multiple prior therapies
Guideline positioning of complement and FcRn therapies
“several clinical trials have been published for newer targeted therapies in MG, predominantly those that inhibit the complement and neonatal Fc gamma receptor pathways, the roles of which are being slowly established especially in patients unresponsive to conventional therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Targeted therapies after 6 to 12 months of conventional therapy without symptom control: 2026 international consensus
“Clinicians should seek to initiate available targeted therapies* in patients with gMG who have active symptoms and for whom conventional therapy† does not achieve symptom control within 6–12 months or results in excessive treatment-related burden. Use of available targeted therapies as initial treatment (together with standard therapy where indicated) should be driven by clinician judgment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should refer a patient with MG to (or comanage with) a specialist with expertise in MG management if there is no sustained clinical improvement within 3–6 months of treatment initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switching after inadequate response to targeted therapies: German-Austrian expert recommendations
“Recommendation (consensus): An interclass switch should be considered if therapy is ineffective at the appropriate dosage and duration, if intolerable side effects occur, or for patient preferences regarding type and frequency of administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): A switch to IVIg interval therapy should be considered in cases where targeted immunotherapies fail to provide adequate clinical efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): Patients who are clinically stable on IVIg or SCIg interval therapy without intolerable side effects should not be switched to C5‐I or FcRn‐I.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cellular therapy for severe refractory autoimmune disease within clinical trials at accredited centers: EBMT recommendations
“Whenever possible, CT in ADs should be performed in the context of a clinical trial with well-defined end points and eligibility criteria in accordance with GCPs and appropriate regulatory requirements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Such expert centres should have a JACIE accreditation for Immune Effector Cells (IEC) administration and established multidisciplinary team meetings and/or similar processes for CT as for HCT, involving AD specialists and haematologists working in tandem in the same place to support thorough assessment, treatment and follow-up of these high-risk fragile patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lymphodepletion requirement for CAR T-cell therapy in autoimmune disease not established: EBMT recommendations
“Of note, repeated dosing of BCMA CART has been efficacious in MG without LD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If and at what dose LD is needed for effective CART in AD is currently not established. As such, LD follows oncological guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CAR T-cell therapy in autoimmune neurological disease: experimental status, specialized centers, and complications
“Possible complications from CAR-T cells (box 1) are extensive and limit the use of these therapies to patients with ‘severe’ or ‘refractory’ autoimmune disease that is not otherwise responsive to existing treatment paradigms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current neurological evidence is limited to small early-phase studies and case reports, with only one placebo-controlled trial (generalised myasthenia gravis).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At present, CAR-T therapy should be considered experimental and delivered in specialised centres, pending longer term safety and durability data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BCMA/CD19 bispecific CAR T-cell therapy after fludarabine and cyclophosphamide lymphodepletion: single-arm phase 1 trial, 18 participants with refractory gMG
“Participants received lymphodepleting chemotherapy with fludarabine (30 mg/m2/day) and cyclophosphamide (300 mg/m2/day) for three consecutive days (days −5 to −3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Between May 3, 2023, and June 19, 2024, 18 patients were enrolled and received apheresis and a single CAR T cell infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The anti-BCMA/CD19 bispecific CAR T cells were generally safe, with no dose-limiting toxicities, no immune effector cell-associated neurotoxicity syndrome, and only grade 1 cytokine release syndrome (39% of patients). The most common grade 3 or worse adverse events within 28 days were hematological toxicities, including three leukopenia, three neutropenia, one anaemia, and one thrombocytopenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“17 participants completed follow-up. Clinical improvements by day 180 were −8.6 (95% CI −10.2 to −7.0) for MG-ADL score and −15.4 (−17.6 to −13.2) for QMG score. 14 participants (82%) achieved minimal manifestations, 15 (88%) stopped glucocorticoids, all stopped non-steroidal immunosuppressants, and eight (47%) had anti-acetylcholine receptor antibody negative seroconversion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CD19 CAR T-cell therapy after lymphodepletion: case series of 3 participants with refractory AChR antibody-positive MG
“We report on three patients with severe, treatment-resistant MG, including one patient with concomitant rheumatoid arthritis, treated with autologous, fully human anti-CD19 CAR T cells. All three patients achieve rapid, sustained clinical MG remission for at least 19 months, allowing discontinuation of MG-specific immunotherapies and substantial improvement in clinical and functional outcomes despite persistent detectable anti-AChR autoantibody titers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A second-generation investigational CAR T cell product (KYV-101, Kyverna Therapeutics) was used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Instead, it may at least partially be attributed to the effects of lymphodepletion (cyclophosphamide and fludarabine), which from approximately day −6 before CAR T cell infusion markedly reduces circulating immune effector cells capable of mediating antibody-dependent inflammation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BCMA CAR T-cell therapy after lymphodepletion: 2 participants with refractory AChR or MuSK antibody-positive MG
“We reported here chimeric antigen receptor (CAR) T cells targeting BCMA in two patients with highly relapsed and refractory myasthenia gravis (one with AChR-IgG, and one with MuSk-IgG). Both patients exhibited favorable safety profiles and persistent clinical improvements over 18 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants stopped all immunosuppressants and steroid one to three days before treatment initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CD19 CAR T-cell therapy in concomitant MG and Lambert-Eaton myasthenic syndrome: 2 participants
“Two women diagnosed with concomitant MG/LEMS experienced severe, increasing disease activity despite multiple immunotherapies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Within 2 months, both patients returned to everyday life, from wheelchair dependency to bicycling and mountain hiking, and remain stable at 6 and 4 months post-CAR T cell infusion, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ongoing CD19 CAR T-cell trials in gMG with and without lymphodepletion: KYSA-6 and RESET-MG
FDA elimination of REMS for approved autologous CAR T-cell therapies, June 2025
Outpatient administration of commercial CAR T-cell therapy in hematologic malignancies: 58 participants, 2022 to 2023
“Patients were seen daily in the cancer center day hospital for the first 7 to 10 days and then twice weekly through day 30.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty-eight patients received outpatient CAR T-cell infusion (33 myeloma, 24 lymphoma, and 1 acute lymphoblastic leukemia). Of these, 17 (41%), 16 (38%), and 9 patients (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30 after CAR T-cell infusion, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hospitalization was prevented in 15 of 35 patients who received tocilizumab for CRS as an outpatient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote